Frontiers in Medicine (Aug 2023)

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

  • Yanis Merad,
  • Anne Conrad,
  • Anne Conrad,
  • Anne Conrad,
  • Anne Conrad,
  • Sophie Brosset,
  • Sophie Brosset,
  • Axel Schmidt,
  • Axel Schmidt,
  • Camille Hanriat,
  • Camille Hanriat,
  • Sebastien Lustig,
  • Sebastien Lustig,
  • Sebastien Lustig,
  • Frederic Laurent,
  • Frederic Laurent,
  • Frederic Laurent,
  • Frederic Laurent,
  • Camille Kolenda,
  • Camille Kolenda,
  • Camille Kolenda,
  • Camille Kolenda,
  • Tiphaine Roussel-Gaillard,
  • Tiphaine Roussel-Gaillard,
  • Tiphaine Roussel-Gaillard,
  • Cecile Batailler,
  • Cecile Batailler,
  • Cecile Batailler,
  • Tristan Ferry,
  • Tristan Ferry,
  • Tristan Ferry,
  • Tristan Ferry,
  • Lyon BJI Study group

DOI
https://doi.org/10.3389/fmed.2023.1224922
Journal volume & issue
Vol. 10

Abstract

Read online

Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of infections involving these strains, little to no clinical data support the use of this association for the treatment of bone and joint infections. We report two cases of complex bone and joint infections involving metallo-beta-lactamase-producing Enterobacterales, successfully treated at our referral center with aztreonam and ceftazidime-avibactam for 12 weeks in continuous infusions through elastomeric infusors.

Keywords